Table 1 Demographic characteristics, comorbidities, and laboratory test results for patients with HA bacterial/fungal infections and non-HA infections at baseline
Characteristics | Total (N = 1778) | HA infection (N = 84) | Non-HA infection (N = 1694) | c2/W | P |
|---|---|---|---|---|---|
Gender [n,%] | 0.08 | 0.78 | |||
male | 1043(58.66) | 51(60.71) | 992(58.56) | ||
female | 735(41.34) | 33(39.29) | 702(43.44) | ||
Age*, year [M, IQR] | 69(56,80) | 75(60,86.25) | 68(56,79) | 54,978 | < 0.001 |
BMI*, kg/m2 [M, IQR] | 23.39(21.20,25.95) | 22.59(19.82,24.34) | 23.43(21.25,26.03) | 27,744 | 0.04 |
Hypertension [n,%] | 1.34 | 0.25 | |||
Yes | 896(50.39) | 48(57.14) | 848(50.06) | ||
No | 882(46.61) | 36(42.86) | 846(49.94) | ||
Diabetes [n,%] | 33.93 | < 0.001 | |||
Yes | 470(26.43) | 47(55.95) | 423(24.97) | ||
No | 1308(73.56) | 37(44.05) | 1271(75.03) | ||
Tumor [n,%] | 0.59 | 0.44 | |||
Yes | 455(25.59) | 25(29.76) | 430(25.38) | ||
No | 1323(74.41) | 59(70.24) | 1264(74.62) | ||
Kidney disease [n,%] | 8.47 | 0.004 | |||
Yes | 655(36.84) | 44(52.38) | 611(36.07) | ||
No | 1123(63.16) | 40(47.62) | 1083(63.93) | ||
Neurological disease [n,%] | 24.14 | < 0.001 | |||
Yes | 571(32.11) | 48(57.14) | 523(30.87) | ||
No | 1207(67.89) | 36(42.86) | 1171(69.13) | ||
Operation[n,%] | 0.09 | 0.76 | |||
Yes | 351(19.74) | 15(17.86) | 336(19.83) | ||
No | 1427(80.26) | 69(82.14) | 1358(80.17) | ||
ICU admission [n,%]: | 11.24 | < 0.001 | |||
Yes | 111(6.24) | 13(15.48) | 98(5.79) | ||
No | 1667(93.76) | 71(84.52) | 1596(94.21) | ||
Treatments before coinfections | |||||
Invasive ventilation (IV)[n,%] | 49.65 | < 0.001 | |||
Yes | 224(12.60) | 32(38.10) | 192(11.33) | ||
No | 1554(87.40) | 52(61.90) | 1502(88.67) | ||
Urinary catheter (UC)[n,%] | 58.08 | < 0.001 | |||
Yes | 566(31.83) | 59(70.24) | 507(29.93) | ||
No | 1212(68.17) | 25(29.76) | 1187(70.07) | ||
Central venous catheter(CVC)[n,%] | 53.34 | < 0.001 | |||
Yes | 433(24.35) | 49(58.33) | 384(22.67) | ||
No | 1345(75.65) | 35(41.67) | 1310(77.33) | ||
Dexamethasone (DXM)[n,%] | 21.69 | < 0.001 | |||
Yes | 537(30.20) | 45(53.57) | 492(29.04) | ||
No | 1241(69.80) | 39(46.43) | 1202(70.96) | ||
Meprednisone(MEP) [n,%] | 2.33 | 0.13 | |||
Yes | 594(33.41) | 35(41.67) | 559(33.00) | ||
No | 1184(66.59) | 49(58.33) | 1135(67.00) | ||
Tocilizumab**(TZ)[n,%] | 1 | ||||
Yes | 21(1.18) | 1(1.19) | 20(1.18) | ||
No | 1757(98.82) | 83(98.81) | 1674(98.81) | ||
Laboratory test results on admission | |||||
White blood cell count(WBC)*, 109/L[M, IQR] | 6.20(4.70,8.50) | 7.70(5.50,10.20) | 6.10(4.70,8.40) | 53,210 | < 0.001 |
Neutrophil percent*,% [M, IQR] | 70.21(59.80,82.20) | 79.7(67.60,90.50) | 70.6(59.50,81.60) | 47,654 | 3.818e-07 |
Lymphocyte count(Lym)*, [M, IQR] | 1.10(0.70,1.60) | 0.90(0.58,1.33) | 1.1(0.70,1.60) | 83,667 | 0.005 |
PCT*, ng/ml[M, IQR] | 0.07(0.04,0.25) | 0.14(0.07,1.50) | 0.071(0.04,0.20) | 34,758 | 4.473e-06 |
IL-6*,pg/ml[M, IQR] | 22.52(7.49,54.31) | 18.02(5.54,42.82) | 22.67(7.69,56.10) | 33,935 | 0.14 |
CRP*, mg/L[M, IQR] | 12.10(4.10,47.88) | 50.30(10.50,114.15) | 10.90(3.90,45.30) | 44,401 | 1.936e-07 |
Albumin*(ALB), g/L [M, IQR] | 36.20(52.00,39.20) | 33.00(29.10,35.88) | 36.3(32.60,39.30) | 94,897 | 1.452e-08 |
Creatinine(Cr)*, umol/L[M, IQR] | 65.00(52.00,86.90) | 75.00(54.75,110.00) | 65.00(52.00, 85.18) | 61,231 | 0.07146 |
Hemoglobin(Hb)*, g/L [M, IQR] | 120(104,133) | 112.5(95.75,126.50) | 120(104,133) | 80,214 | 0.04 |
Glucose(Glu)*, mmol/L [M, IQR] | 6.584(4.52,7.29) | 6.705(5.01,10.69) | 5.26(4.50,7.14) | 48,508 | 5.007e-06 |
Length of hospital stay*, day [M, IQR] | 13.12(7.00,16.00) | 13.00(6.00,19.00) | 11.00(7.00,16.00) | 68,409 | 0.55 |
Neutrophil and lymphocyte ratio(NLR)*,[M, IQR] | 3.73(2.08,7.61) | 6.25(2.83,17.45) | 3.69(2.06,7.43) | 51,301 | 2.036e-05 |
Ferritin*(Fe), ng/ml[M, IQR] | 366.4(185.5,710.7) | 491.80(343.25,1036.7) | 355.7(173.15,690.95) | 11,922 | < 0.001 |